Xin-an Lu

No. 8 Shengmingyuan Road
Changping, 102200, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

MUC18-Directed chimeric antigen receptor T cells for the treatment of mucosal melanoma.

MUC18-Directed chimeric antigen receptor T cells for the treatment of mucosal melanoma.

Journal: Journal of translational medicine

Published: November 16, 2024

Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion.

Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion.

Journal: Frontiers in oncology

Published: January 14, 2022

Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.

Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.

Journal: Cancer immunology, immunotherapy : CII

Published: January 27, 2021

Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies.

Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies.

Journal: BMC cancer

Published: August 30, 2020

The clinical outcomes of fresh versus cryopreserved CD19-directed chimeric antigen receptor T cells in non-Hodgkin lymphoma patients.

The clinical outcomes of fresh versus cryopreserved CD19-directed chimeric antigen receptor T cells in non-Hodgkin lymphoma patients.

Journal: Cryobiology

Published: April 10, 2020

Production of lentiviral vectors in suspension cells using low proportion of supercoiled circular plasmid DNA.

Production of lentiviral vectors in suspension cells using low proportion of supercoiled circular plasmid DNA.

Journal: Cytotechnology

Published: March 18, 2020

Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia.

Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia.

Journal: Molecular therapy oncolytics

Published: February 26, 2020

Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features.

Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features.

Journal: Blood advances

Published: January 09, 2020

Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma.

Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma.

Journal: Molecular therapy oncolytics

Published: May 05, 2019

Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma.

Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma.

Journal: Cancer gene therapy

Published: September 11, 2018

The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing.

The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing.

Journal: Cellular immunology

Published: November 19, 2015

Specific chemotherapeutic agents induce metastatic behaviour through stromal- and tumour-derived cytokine and angiogenic factor signalling.

Specific chemotherapeutic agents induce metastatic behaviour through stromal- and tumour-derived cytokine and angiogenic factor signalling.

Journal: The Journal of pathology

Published: December 16, 2014

Showing 1-12 of 17

Last Updated: 09/26/2026